Boston Scientific Starts Trial For EkoSonic Endovascular System In Patients With Pulmonary Embolism

Boston Scientific Corporation BSX began enrollment for a clinical trial of its EkoSonic endovascular system (EKOS).
Boston Scientific’s HI-PEITHO trial, a collaborative research study, will compare EkoSonic in combination with anticoagulation to anticoagulation alone for treating acute, intermediate-high-risk pulmonary embolism (PE).
EKOS uses ultrasound energy combined with the thrombolytic drug to dissolve blood clots and restore blood flow in patients with PE and peripheral arterial occlusions.
EKOS ultrasound technology accelerates thrombolysis by minimizing the time it takes to treat a patient and lowering the necessary thrombolytic dose, reducing the risk of bleeding.
The randomized HI-PEITHO trial will enroll up to 544 patients.
Boston Scientific said the composite primary endpoint is PE-related mortality, cardiorespiratory decompensation or collapse, and non-fatal symptomatic and objectively confirmed recurrence of PE.
Price Action: BSX shares are down 1.83% at $44.71 during the market session on the last check Wednesday.

Momentum89.47

Growth76.31

Quality65.82

Value11.35

Short

Medium

Long